SURUNKALI YALLIG‘LANISH JARAYONLARIDA SITOKINLAR MUVOZANATINING KLINIK AHAMIYATI

Article Sidebar

PDF
Выпуск: Том 4 № 1 Part 2 : Центральноазиатский журнал академических исследований
Раздел: Статьи
Опубликован:

Main Article Content

EMU University
bakhtiyarovna_duri@icloud.com

Аннотация:

Surunkali yallig‘lanish jarayonlari zamonaviy tibbiyotda ko‘plab ichki a’zolar kasalliklarining rivojlanishida yetakchi patogenetik omillardan biri sifatida qaraladi. Yallig‘lanishning uzoq davom etishi immun tizim faoliyatining buzilishi bilan chambarchas bog‘liq bo‘lib, ayniqsa sitokinlar tizimidagi muvozanatning izdan chiqishi ushbu jarayonning surunkali tus olishiga sabab bo‘ladi. Proyallig‘lanish sitokinlarining haddan tashqari faollashuvi va antienflamator mediatorlarning yetishmovchiligi natijasida to‘qimalarda destruktiv o‘zgarishlar yuzaga keladi, kasallikning klinik kechishi og‘irlashadi hamda asoratlar rivojlanish xavfi ortadi. Ushbu maqolada surunkali yallig‘lanish jarayonlarida sitokinlar muvozanatining buzilish mexanizmlari, ularning immun javob shakllanishiga ta’siri va klinik ahamiyati ilmiy adabiyotlar tahlili asosida yoritilgan. Shuningdek, sitokinlarni nazorat qilishga qaratilgan zamonaviy terapevtik yondashuvlarning amaliy ahamiyati ko‘rib chiqilgan.

Ключевые слова:

Article Details

Как цитировать:

O’tkirova, D. (2026). SURUNKALI YALLIG‘LANISH JARAYONLARIDA SITOKINLAR MUVOZANATINING KLINIK AHAMIYATI. Центральноазиатский журнал академических исследований, 4(1 Part 2), 67–71. извлечено от https://in-academy.uz/index.php/cajar/article/view/73122

Библиографические ссылки:

Smith, J. (2021). Cytokines in chronic inflammation. Medical Journal, 18(3), 145–152.

Petrov, A. (2020). Immunology and chronic diseases. Clinical Medicine, 12(2), 89–96.

Ivanov, V. (2019). Role of cytokines in pathology. Immunology Review, 10(1), 34–40.

Brown, L., & Davis, K. (2022). Cytokine balance and chronic inflammation: Clinical perspectives. Journal of Translational Medicine, 20(5), 200–210.

Zhang, H., & Li, Y. (2021). IL-6 and TNF-α as biomarkers in chronic inflammatory diseases. International Journal of Immunopathology and Pharmacology, 35, 1–12.